Ask the Expert: How can patient-derived organoids accelerate KRAS drug development?

RAS proteins have been considered undruggable for several reasons. First, they have a very smooth surface without well-defined binding pockets, making it difficult for small molecule inhibitors to bind tightly and precisely.